biostudies-literatureDurand CMCCR NIH HHSNational Institute of Allergy and Infectious DiseasesNIAID NIH HHSNational Cancer InstituteNCI NIH HHSNational Institutes of HealthNIH HHS853-864https://www.ebi.ac.uk/biostudies/studies/S-EPMC9997133biostudies-literatureUnknown22(3)Liver transplantation (LT) from donors-with-HIV to recipients-with-HIV (HIV D+/R+) is permitted under the HOPE Act. There are only three international single-case reports of HIV D+/R+ LT, each with limited follow-up. We performed a prospective multicenter pilot study comparing HIV D+/R+ to donors-without-HIV to recipients-with-HIV (HIV D-/R+) LT. We quantified patient survival, graft survival, rejection, serious adverse events (SAEs), human immunodeficiency virus (HIV) breakthrough, infections, and malignancies, using Cox and negative binomial regression with inverse probability of treatment weighting. Between March 2016-July 2019, there were 45 LTs (8 simultaneous liver-kidney) at 9 centers: 24 HIV D+/R+, 21 HIV D-/R+ (10 D- were false-positive). The median follow-up time was 23 months. MAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant SurgeonsHOPE in action: A prospective multicenter pilot study of liver transplantation from donors with HIV to recipients with HIV.PMC9997133P30 CA006973U01 AI13889775N91019D00024R01 AI1209383P30CA0069731P30AI0941891R01AI120938HHSN261200800001EHHSN261200800001CK24 AI144954U01AI138897U01 AI134591U01AI134591P30 AI094189Liang TCooper MBenamu EBasinger KRasmussen SKirchner VAKitchens WSpaggiari MKubal CSugarman JSrisengf TNeumann HLocke JEMuthukumar TSchaenman JBoyarsky BSawinski DKwan JLyon GMSegev DLHuckaby JPrice JCCochran WVKramer SDurand CMElias NRoberson ABarnaba BTurgeon NChin-Hong PMorrison MJeffery ARana MMOdim JStock PYu SHusson JMiller JSmith ARBlumberg EATomlin RWojciechowski DWeldon EPMotter JDCharles CNagy JOttmann SEdwards CThomas MMorris MIFerry EBaah WFlorman SWhitby DOstrander DTimpone JWolfe CHughes Kramer KAdebiyi MHaidar GGallon LLabo NAslam SCarlson ETobian AARPereira MMarrazzo IDBrigle NFriedman-Moraco RLink KAdebiyi OEby YDesai NNKlein EKusemiju OBismut GAmbinder RKirby CDeterville CMompoint-Williams DApewokin SPearson TBollinger JDunn TGoudy LHamilton JPBrown DSchmidt HMall MKlock EAgarwal AMiley WRedd ADBowring MGGupta GMehta SPakstis DLMehta AKCastillo-Lugo JADieter RHand JBrogden GWerbel WASimkins JMehta SAGilbert ALa Hoz RMElbein RWilkinson RQuinn TCDoby BAkhran ASeaman SSantos CAQPruett TStosor VTownsend MBruno KMalinis MMekeel KHuprikar SMorsheimer MHaydel BMCameron AHOPE in Action InvestigatorsRogers RFarnsworth MCoakley MRanganna KMHarrison KMunoz CDonaghy EPiquant DDoyle AStucke AMassie ANguyen PSilveira FPrizzi MChao AGadzhyan JJohnstone JFernandez REBaldecchi MButkus-Small CfalseHOPE in action: A prospective multicenter pilot study of liver transplantation from donors with HIV to recipients with HIV.Liver transplantation (LT) from donors-with-HIV to recipients-with-HIV (HIV D+/R+) is permitted under the HOPE Act. There are only three international single-case reports of HIV D+/R+ LT, each with limited follow-up. We performed a prospective multicenter pilot study comparing HIV D+/R+ to donors-without-HIV to recipients-with-HIV (HIV D-/R+) LT. We quantified patient survival, graft survival, rejection, serious adverse events (SAEs), human immunodeficiency virus (HIV) breakthrough, infections, and malignancies, using Cox and negative binomial regression with inverse probability of treatment weighting. Between March 2016-July 2019, there were 45 LTs (8 simultaneous liver-kidney) at 9 centers: 24 HIV D+/R+, 21 HIV D-/R+ (10 D- were false-positive). The median follow-up time was 23 months. M2022-01-01T00:00:00Z2022 Mar2026-05-28T10:49:45.193Z2024-11-19T16:22:37.313ZS-EPMC99971333474180010.1111/ajt.16886